Erratum: Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Mikropoulos, Christos; Selkirk, Christina G.; Saya, Sibel; Bancroft, Elizabeth; Vertosick, Emily; Dadaev, Tokhir; Brendler, Charles B.; Page, Elizabeth; Dias, Alexander; Evans, D. Gareth; Rothwell, Jeanette; Mæhle, Lovise; Axcrona, Karol; Richardson, Kate; Eccles, Diana M.; Jensen, Thomas D.; Osther, Palle Jørn Sloth; Asperen, Christi J. van; Vasen, Hans F. A.; Kiemeney, Lambertus A.; Ringelberg, Janneke; Cybulski, Cezary; Wokołorczyk, Dominika; Hart, Rachel; Glover, Wayne; Lam, Jimmy; Taylor, Louise; Salinas, Mónica; Feliubadaló, Lídia; Oldenburg, Rogier A.; Cremers, R.G.H.M.; Verhaegh, Gerald W.; Zelst-Stams, Wendy A. van; Oosterwijk, Jan C.; Cook, Jackie; Rosario, Derek J.; Buys, Saundra S.; Conner, Thomas; Domchek, Susan M.; Powers, Jacquelyn; Ausems, Margreet G. E. M.; Teixeira, Manuel R.; Maia, Sofia; Izatt, Louise; Schmutzler, Rita; Rhiem, Kerstin; Foulkes, William D.; Boshari, Talia; Ruijs, Mariëlle

doi:10.1038/bjc.2018.11

Cited by 4 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis of the baseline screen for nearly 2500 men enrolled in IMPACT supported the use of targeted PSA screening in BRCA1/2 mutation carriers, suggesting that screening detects a high proportion of clinically significant tumours [22]. Moreover, we have also demonstrated that PSA is more predictive of PrCa in BRCA1/2 carriers than in noncarriers [23]. It has been reported that men with germline BRCA1/ BRCA2 mutations, on active surveillance for low-risk PrCa, are at a higher risk of reclassification to higher-grade PrCa than noncarriers [24].…”

Section: Introductionsupporting

confidence: 54%

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundMutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations.ObjectiveTo report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status.Design, setting, and participantsMen aged 40–69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy.Outcome measurements and statistical analysisPSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians.Results and limitationsA total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65).ConclusionsAfter 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers.Patient summaryWe demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.

show abstract

Section: Introductionsupporting

confidence: 54%

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Bei BRCA-Mutation ist PSA-Wert aussagekräftiger

Schumacher¹

2018

Uro-News

View full text Add to dashboard Cite

Screening naar prostaatkanker bij mannen met een BRCA2 mutatie: adviezen voor de praktijk gebaseerd op resultaten van internationale studie

Asperen

Bangma

2020

Tijdschr Urol

View full text Add to dashboard Cite

Samenvatting Mannen die drager zijn van een BRCA2 mutatie (BRCA2+ mannen of BRCA2 dragers) hebben een verhoogd risico op prostaatkanker ten opzichte van mannen zonder mutatie. Daarnaast betreft het vaker agressievere tumoren. De resultaten van de internationale IMPACT-studie laten zien dat de BRCA2+ mannen relatief veel baat kunnen hebben van screening naar prostaatkanker. In totaal werden 2.932 mannen gerekruteerd. Na vier screeningsrondes met PSAbepaling is aangetoond dat BRCA2 dragers een statistisch-significante hogere kans hebben op prostaatcarcinoom, 19 per 1.000, in vergelijking met niet-dragers, 12 per 1.000 (p = 0,03). Ook betreft het vaker klinischsignificante prostaatcarcinomen (77%) in vergelijking met 49% in de algemene populatie. Op basis van de resultaten van de IMPACT-studie is besloten om in Nederland de mogelijkheid van screening voor prostaatkanker actief te bespreken met BRCA2+ mannen. Trefwoorden BRCA2 mutatie • prostaatkanker • IMPACT-studie • screening Screening for prostate cancer in men with a BRCA2 mutation: recommendations for daily practice based on the results of an international study Abstract Men who carry a BRCA2 mutation (BRCA2+ men or BRCA2 carriers) have an increased risk for prostate cancer, also tumors are more aggressive. The prof. dr. C. J. van Asperen ()

show abstract

Erratum: Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Cited by 4 publications

References 26 publications

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Bei BRCA-Mutation ist PSA-Wert aussagekräftiger

Screening naar prostaatkanker bij mannen met een BRCA2 mutatie: adviezen voor de praktijk gebaseerd op resultaten van internationale studie

Contact Info

Product

Resources

About